Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-Acetyl Cysteine Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

NAC for Attenuation of COVID-19 Symptomatology

NCT05074121
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Lower Respiratory Infection, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine, Placebo
Drug · Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Everett, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 30, 2026, 3:44 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of N-acetylcysteine in Patients With COVID-19 Infection

NCT04374461
View directory record Official record
Conditions
Covid-19
Interventions
N-acetylcysteine, Peripheral Blood
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Antioxidant Treatment of Type 2 Diabetes

NCT00609102
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, n-aceylcysteine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

NCT00374088
View directory record Official record
Conditions
Transposition of Great Vessels, Congenital Heart Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 3 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

NCT00028262
View directory record Official record
Conditions
Infantile Neronal Ceroid Lipofuscinosis
Interventions
Cystagon
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 3 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 30, 2026, 3:44 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia

NCT01905696
View directory record Official record
Conditions
Focus is Determination of the Role of SNO-Hb in Forearm Blood Flow Regulation
Interventions
Oral N-acetylcysteine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Not applicable Interventional Results available

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT04073368
View directory record Official record
Conditions
NAFLD
Interventions
AXA1957, AXA1125, Placebo
Dietary Supplement
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Not applicable Interventional Results available

Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes

NCT01394510
View directory record Official record
Conditions
Type 2 Diabetes, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Utzschneider, Kristina, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 30, 2026, 3:44 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02569957
View directory record Official record
Conditions
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Topotecan Hydrochloride, Acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Sep 30, 2026, 3:44 PM EDT
Active, not recruiting Phase 1 Interventional

FIGHT-RP 1 Extension Study

NCT03999021
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
NAC effervescent tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

NCT01612221
View directory record Official record
Conditions
Patients at Risk for Melanoma
Interventions
N-acetylcysteine, Placebo arm
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Glutathione and Fuel Oxidation in Aging

NCT01870193
View directory record Official record
Conditions
Aging
Interventions
Glycine, cysteine (as n-acetylcysteine), alanine
Dietary Supplement
Lead sponsor
Rajagopal V Sekhar
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 30, 2026, 3:44 PM EDT
Active, not recruiting Phase 2 Interventional

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104
View directory record Official record
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 30, 2026, 3:44 PM EDT
Active, not recruiting Phase 2 Interventional

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 30, 2026, 3:44 PM EDT
Terminated Phase 4 Interventional Results available

Clinical Trial of NAC in Asthma

NCT02605824
View directory record Official record
Conditions
Asthma
Interventions
n-acetylcystine, 0.9% saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 30, 2026, 3:44 PM EDT
Completed No phase listed Observational

Treatment of Acetaminophen Toxicity With N-acetylcysteine

NCT00725179
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)

NCT00724594
View directory record Official record
Conditions
Chorioamnionitis, Brain Injury
Interventions
N-acetylcysteine, Control
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 30, 2026, 3:44 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 30, 2026, 3:44 PM EDT
Completed No phase listed Observational

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

NCT01465542
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Sep 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Results available

Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents

NCT04005053
View directory record Official record
Conditions
Self-Harm, Depression, Suicide
Interventions
N-acetyl cysteine, Placebo oral tablet
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 30, 2026, 3:44 PM EDT